Join        Login             Stock Quote

Medicis (MRX) Drops After Disclosing Q-Med Suit Related To Valeant (VRX) Merger

 November 09, 2012 01:47 PM

(By Balachander) Medicis Pharmaceutical Corp. (NYSE: MRX) shares are down sharply after disclosing that Q-Med has filed a suit against the company related to Medicis' merger with Valeant Pharmaceuticals International Inc. (NYSE: VRX).

Medicis holds exclusive U.S. and Canadian rights to market certain dermal filler products, including RESTYLANE, RESTYLANE-L, PERLANE, PERLANE-L and RESTYLANE FINE LINES, through certain license and supply agreements with Q-Med.

The lawsuit alleges that Q-Med has the right to withhold consent to a change of control of Medicis that would result in a transfer to Valeant of the exclusive rights to market and sell the dermal filler products.

[Related -Three Stocks Set For FDA News In Early December]

Valeant agreed to acquire Medicis for roughly $2.6 billion or $44.00 per share in cash in September. 

Q-Med alleges that the action is in aid of arbitration to prevent Medicis from transferring such rights to Valeant as a result of the merger. Q-Med seeks a preliminary injunction prohibiting Medicis from transferring its rights to Valeant during the pendency of the arbitration proceedings that Q-Med will bring.

Medicis believes that Q-Med's action is without merit and intends to vigorously defend itself, the company said in a filing with the U.S. Securities and Exchange Commission (SEC).

Medicis shares, which have been trading in the 52-week range of $29.76 to $43.70, fell 4.96 percent or $2.16 to trade at $41.20 on Friday. Valeant shares added 0.39 percent.

iOnTheMarket Premium


Post Comment -- Login is required to post message
Alert for new comments:
Your email:
Your Website:

rss feed

Latest Stories

article imageEmerging-Markets Stocks Took The Lead Last Week

Emerging-markets equities enjoyed a solid rise last week among the major asset classes, based on a set of read on...

article imageDoes Your Latest Investment Pass This Test?

On Wednesday, I sounded the alarm about the problems looming for some consumer staples stocks. In short, read on...

article imageIs The Slump In US Manufacturing Easing?

Yesterday’s November survey data from the Philadelphia Fed hints at the possibility that a stronger trend read on...

article imageMarket Potentially Facing Near Term Technical Headwinds

After the S&P 500 Index pullback on Thursday and Friday last week, the market's advance on Monday and read on...

Popular Articles

Daily Sector Scan
Partner Center

Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.